CDNA vs. PSNL, GTH, BNR, GH, FTRE, VCYT, VRDN, FLGT, CELC, and CSTL
Should you be buying CareDx stock or one of its competitors? The main competitors of CareDx include Personalis (PSNL), Genetron (GTH), Burning Rock Biotech (BNR), Guardant Health (GH), Fortrea (FTRE), Veracyte (VCYT), Viridian Therapeutics (VRDN), Fulgent Genetics (FLGT), Celcuity (CELC), and Castle Biosciences (CSTL).
CareDx (NASDAQ:CDNA) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.
CareDx presently has a consensus target price of $17.00, suggesting a potential downside of 10.57%. Personalis has a consensus target price of $5.00, suggesting a potential upside of 44.93%. Given Personalis' stronger consensus rating and higher possible upside, analysts plainly believe Personalis is more favorable than CareDx.
CareDx has a net margin of -66.59% compared to Personalis' net margin of -124.89%. CareDx's return on equity of -55.08% beat Personalis' return on equity.
CareDx received 320 more outperform votes than Personalis when rated by MarketBeat users. Likewise, 66.31% of users gave CareDx an outperform vote while only 65.68% of users gave Personalis an outperform vote.
61.9% of Personalis shares are owned by institutional investors. 4.2% of CareDx shares are owned by insiders. Comparatively, 4.1% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
CareDx has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500.
Personalis has lower revenue, but higher earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.
In the previous week, CareDx had 2 more articles in the media than Personalis. MarketBeat recorded 6 mentions for CareDx and 4 mentions for Personalis. Personalis' average media sentiment score of 0.94 beat CareDx's score of 0.92 indicating that Personalis is being referred to more favorably in the news media.
Summary
CareDx beats Personalis on 9 of the 17 factors compared between the two stocks.
Get CareDx News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
